Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

<p>Supplemental Figure S2: Amino acid sequence alignment of CLDN6 (P56747) and CLDN9 (O95484) with the extracellular loops highlighted</p>

Сохранить в:

Библиографические подробности
Главный автор:	Martina S.J. McDermott (15206951) (author)
Другие авторы:	Neil A. O'Brien (15206954) (author), Benjamin Hoffstrom (15206957) (author), KeWei Gong (15206960) (author), Ming Lu (15206963) (author), Jun Zhang (15206966) (author), Tong Luo (15206969) (author), Min Liang (15206972) (author), Weiping Jia (15206975) (author), Jenny J. Hong (15206978) (author), Kevin Chau (15206981) (author), Simon Davenport (15206984) (author), Bin Xie (15206987) (author), Michael F. Press (15206990) (author), Richard Panayiotou (15206993) (author), Abram Handly-Santana (15206996) (author), Joan S. Brugge (9710515) (author), Leonard Presta (15206999) (author), John Glaspy (15207002) (author), Dennis J. Slamon (15047067) (author)
Опубликовано:	2025
Предметы:	Cancer Therapeutic Research and Development Biological Agents & Therapies Antibody-drug conjugates Gynecological Cancers Endometrial cancer Ovarian cancer Translational Research
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!

Схожие документы

Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
по: Martina S.J. McDermott (15206951)
Опубликовано: (2025)

Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
по: Martina S.J. McDermott (15206951)
Опубликовано: (2025)

Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
по: Martina S.J. McDermott (15206951)
Опубликовано: (2025)

Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
по: Martina S.J. McDermott (15206951)
Опубликовано: (2025)

Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
по: Martina S.J. McDermott (15206951)
Опубликовано: (2025)

Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
по: Martina S.J. McDermott (15206951)
Опубликовано: (2025)

Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
по: Martina S.J. McDermott (15206951)
Опубликовано: (2025)

Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
по: Martina S.J. McDermott (15206951)
Опубликовано: (2025)

Supplementary Tables from Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
по: Santiago Duro-Sánchez (14959182)
Опубликовано: (2025)

Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
по: Yuncheng Bei (16546095)
Опубликовано: (2025)

Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
по: Yuncheng Bei (16546095)
Опубликовано: (2025)

Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
по: Yuncheng Bei (16546095)
Опубликовано: (2025)

Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
по: Kristoffer Staal Rohrberg (15009138)
Опубликовано: (2025)

Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
по: Kristoffer Staal Rohrberg (15009138)
Опубликовано: (2025)

Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
по: Kristoffer Staal Rohrberg (15009138)
Опубликовано: (2025)

Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
по: Kristoffer Staal Rohrberg (15009138)
Опубликовано: (2025)

Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
по: Kristoffer Staal Rohrberg (15009138)
Опубликовано: (2025)

Table 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
по: Kristoffer Staal Rohrberg (15009138)
Опубликовано: (2025)

Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
по: Kristoffer Staal Rohrberg (15009138)
Опубликовано: (2025)

Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
по: Kristoffer Staal Rohrberg (15009138)
Опубликовано: (2025)

Table 4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
по: Kristoffer Staal Rohrberg (15009138)
Опубликовано: (2025)

Table S6 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
по: Xiaoqing Cheng (16918496)
Опубликовано: (2025)

Supplementary Table S6 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
по: Erwin Tomasich (15052256)
Опубликовано: (2025)

Figures S1-S2 from Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
по: Sheheryar Kabraji (15050565)
Опубликовано: (2025)

Table 1_Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation.xlsx
по: Yueren Fan (22687577)
Опубликовано: (2025)

Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
по: Xiaoqing Cheng (16918496)
Опубликовано: (2025)

Table S2 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
по: Xiaoqing Cheng (16918496)
Опубликовано: (2025)

Table S3 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
по: Xiaoqing Cheng (16918496)
Опубликовано: (2025)

Table S4 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
по: Xiaoqing Cheng (16918496)
Опубликовано: (2025)

Table S5 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
по: Xiaoqing Cheng (16918496)
Опубликовано: (2025)

Supplementary Table S1 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
по: Erwin Tomasich (15052256)
Опубликовано: (2025)

Supplementary Table S2 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
по: Erwin Tomasich (15052256)
Опубликовано: (2025)

Supplementary Table S3 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
по: Erwin Tomasich (15052256)
Опубликовано: (2025)

Supplementary Table S4 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
по: Erwin Tomasich (15052256)
Опубликовано: (2025)

Supplementary Table S5 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
по: Erwin Tomasich (15052256)
Опубликовано: (2025)

Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
по: Niklas Klümper (15048887)
Опубликовано: (2025)

Supplementary Data TS1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
по: Niklas Klümper (15048887)
Опубликовано: (2025)

Image 3_Pan-cancer multi-omics characterization of calcyphosine and its revealed links to the immune microenvironment and regulatory networks in endometrial carcinoma.jpeg
по: Xi Chen (35903)
Опубликовано: (2025)

Table 2_Pan-cancer multi-omics characterization of calcyphosine and its revealed links to the immune microenvironment and regulatory networks in endometrial carcinoma.docx
по: Xi Chen (35903)
Опубликовано: (2025)

Table 1_Pan-cancer multi-omics characterization of calcyphosine and its revealed links to the immune microenvironment and regulatory networks in endometrial carcinoma.xlsx
по: Xi Chen (35903)
Опубликовано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_3c48p9klsfa2hb3da5ds29a6be